St. Louis, MO - SAFC, a member of the Sigma-Aldrich Group (Nasdaq: SIAL), has announced the new entity, 'SAFC Supply Solutions,' strategically combining its Specialties business with capabilities of the former Proligo Reagents manufacturing site (Hamburg, Germany), which was acquired from Degussa AG in April 2005.

SAFC Supply Solutions will provide a customized supply of raw materials from its extensive product range, supported by a global supply chain allowing innovative delivery solutions. Offering over 80,000 products, 40,000 of which are manufactured in-house, Supply Solutions' market focus will include organic raw materials for pharmaceuticals, biopharmaceuticals, IVD diagnostics manufacturers and flavors & fragrances. Supply Solutions also supplies a broad range of industries with customized raw materials that meet specific manufacturing requirements.

Manufacturing facilities are located in cities worldwide, including: Steinheim and Hamburg in Germany; Buchs, Switzerland; Sheboygan, Milwaukee and St. Louis in the US; and Gillingham and Poole in the UK. With such an expansive presence Supply Solutions has become the latest discrete segment of SAFC, joining SAFC Pharma, SAFC Biosciences and SAFC Hitech.

"The name 'Supply Solutions' more accurately reflects our ability to provide customized services around our extensive fine chemical and biochemical product range," said SAFC President Frank Wicks.

The creation of SAFC Supply Solutions represents the latest addition to Sigma-Aldrich's strategic plan, launched in 2005. The plan calls for creation of several high performing initiatives in the custom chemical business sector that are expected to drive SAFCs sales to over $400 million and secure its position as a top 10 fine chemical company worldwide.

Drivers for SAFC's continued growth include focus on production, supply chain, systems and customer interaction - together with further product and service offers, notably in Supply Solutions. Add-ons to the current technologies portfolio and SAFC's cGMP capacity are also part of the current strategic agenda.

For more information about SAFC Supply Solutions visit www.safcsupplysolutions.com.

Press Inquiries: Richard Kerns, Northern Exposure PR Tel: +44-161-728-5880

About SAFC: SAFC is the custom-manufacturing group within Sigma-Aldrich that focuses on both biochemical production and the manufacturing of complex, multi-step organic synthesis of APIs and key intermediates. SAFC has manufacturing facilities around the world dedicated to providing manufacturing services for companies requiring a reliable partner to produce their custom manufactured materials.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 35 countries and has over 6,800 employees providing excellent service worldwide. We are committed to accelerating Customer success through leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning Web site at www.sigma-aldrich.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding Sigma-Aldrich's expectations, goals, beliefs, intentions and the like regarding future sales, earnings and other matters. These statements involve assumptions regarding Company operations, investments and conditions in the markets the Company serves. Although the Company believes its expectations are based on reasonable assumptions, such statements are subject to risks and uncertainties, including, among others, certain economic, political and technological factors. Actual results could differ materially from those stated or implied in this news release, due to, but not limited to, such factors as (1) changes in pricing and the competitive environment, (2) other changes in the business environment in which the Company operates, (3) uncertainties surrounding government healthcare reform, (4) government regulations applicable to the business, (5) the impact of fluctuations in foreign currency exchange rates, and (6) the ability to retain customers, suppliers and employees. (7) the success of research and development activities and (8) the impact of acquisitions and success in integrating and obtaining projected results from the acquisitions. The Company does not undertake any obligation to update these forward-looking statements.